Aims and objectives
To investigate the potential benefit of ultrahigh b-value DWI in rectal cancer by qualitatively and quantitatively comparing b=1000 s/mm2 (b1000) and b=2000s/mm2 (b2000) DWI for the detectability and conspicuity of rectal tumors,
using a 3T state of-the-art MR scanner.
Methods and materials
A total of 33 patients (42 rectal MR scans) were retrieved from the hospital’s PACS system between November 2016 and October 2017 to be potentially included in this retrospective study; informed consent was waived.
Inclusion criteria were: pathology proven solid (non-mucinous) rectal cancer; availability of DWI-MR scan (primary staging and/or restaging after neoadjuvant treatment before surgery) of the rectum including b1000 and b2000 images.( Fig.1 - Inclusion and exclusion criteria ) A...
Of the 33 patients (42 MR exams),
3 patients (3 MR exams) were excluded due to biopsy proved mucinous tumors and 2 patients (2 MR exams) were excluded due to nondiagnostic image quality (hip replacement).
7 MR exams with missed pathology (surgery performed after neoadjuvant treatment) were excluded.
A total of 24 patients (29 MR scans) met the inclusion criteria and constituted the final study population (57 ± 12 years,
mean age ± SD). Of the 29 MR scans,
18 (62%) were performed at...
The use of DWI with ultra high b value (b=2000 s/mm2 ) has the potential to improve tumor conspicuity compared to the more commonly used b=1000 s/mm2 in patients with rectal cancer,
especially for readers with limited experience in reading rectal MRI.
Improved conspicuity could be more beneficial in the restaging setting,
where the differentiation between a complete response and small tumor remnant is of major clinical importance in the light of new conservative treatment strategies (i.e....
Department of Radiology and Bioimaging,
Annunziata" - Chieti - Chieti/IT
Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting.
Eur Radiol 2018; 28(4): 1465-75. 2.
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
J Clin Oncol 2011; 29(35): 4633-40. 3.
van der Paardt MP,